Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results

Rhea-AI Summary

Constellation Pharmaceuticals will host a conference call on October 29, 2020, at 8:00 AM EDT to discuss its third quarter 2020 results and clinical progress. The call is open to the public and can be accessed via the Investor Relations section of their website. The company specializes in developing therapeutics targeting gene expression to address significant medical needs in cancer patients. Their pipeline includes the BET inhibitor CPI-0610 for myelofibrosis and the EZH2 inhibitor CPI-0209 for various cancers.

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on October 29, 2020, to discuss its third quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 7374769.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Contacts

Kia Khaleghpour, PhD
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com

Ronald Aldridge
Senior Director, Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539
ron.aldridge@constellationpharma.com

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com

FAQ

When is the Constellation Pharmaceuticals conference call?

The conference call is scheduled for October 29, 2020, at 8:00 AM EDT.

How can I access the Constellation Pharmaceuticals conference call?

You can access the conference call via the Investor Relations section of Constellation Pharmaceuticals' website.

What topics will Constellation Pharmaceuticals cover in the conference call?

The call will discuss their third quarter 2020 results and progress in clinical programs.

What are the key products in Constellation Pharmaceuticals' pipeline?

Key products include the BET inhibitor CPI-0610 for myelofibrosis and the EZH2 inhibitor CPI-0209 for cancer.

Who should I contact for more information about Constellation Pharmaceuticals?

For inquiries, contact Kia Khaleghpour, VP of Investor Relations at +1 617-844-6859.